Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314551 | 0.90 | MEN1 (0.42) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL10314583 | 0.89 | KMT2A (0.44) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL10314575 | 0.89 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL1062302 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL10314576 | 0.85 | ALDH1A1 (0.40) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL17677371 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL1055219 | 0.82 | KMT2A (0.48) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL13708843 | 0.80 | LMNA (0.47) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL1060229 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL3425434 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1ALDH1A1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMN1; SMN2 3564/4885MEN1 1922/4885ALDH1A1 745/4885 |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMN1; SMN2 3559/4885MEN1 2094/4885ALDH1A1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.